Expert Opinion on Pharmacotherapy

[1]  W. Craig,et al.  Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  G. Richard,et al.  Levofloxacin versus ciprofloxacin versus lomefloxacin in acute pyelonephritis. , 1998, Urology.

[3]  G. Eliopoulos,et al.  Susceptibilities of Legionella spp. to Newer Antimicrobials In Vitro , 1998, Antimicrobial Agents and Chemotherapy.

[4]  C. Cox,et al.  A controlled trial of levofloxacin and lomefloxacin in the treatment of complicated urinary tract infection. , 1998, Urology.

[5]  L. Gentry,et al.  Multicenter, randomized study comparing efficacy and safety of oral levofloxacin and cefaclor in treatment of acute bacterial exacerbations of chronic bronchitis , 1998 .

[6]  G L Drusano,et al.  Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. , 1998, JAMA.

[7]  R. Bordet,et al.  Sparfloxacin but not levofloxacin or ofloxacin prolongs cardiac repolarization in rabbit Purkinje fibers , 1998, Fundamental & clinical pharmacology.

[8]  S. Chien,et al.  Levofloxacin Does Not Alter Cyclosporine Disposition , 1998, Journal of clinical pharmacology.

[9]  J. Kahn,et al.  Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. , 1997, Diagnostic microbiology and infectious disease.

[10]  Jeffrey W. Smith,et al.  Multicenter, Randomized Study Comparing Levofloxacin and Ciprofloxacin for Uncomplicated Skin and Skin Structure Infections , 1997, Southern medical journal.

[11]  U. Schaad,et al.  Quinolone arthropathy in animals versus children. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[12]  Y. Kashida,et al.  Characterization of fluoroquinolone-induced Achilles tendon toxicity in rats: comparison of toxicities of 10 fluoroquinolones and effects of anti-inflammatory compounds , 1997, Antimicrobial agents and chemotherapy.

[13]  M. Jacobs,et al.  Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods , 1997, Antimicrobial agents and chemotherapy.

[14]  M. Jacobs,et al.  Susceptibility of twenty penicillin-susceptible and -resistant pneumococci to levofloxacin, ciprofloxacin, ofloxacin, erythromycin, azithromycin, and clarithromycin by MIC and time-kill. , 1997, Diagnostic microbiology and infectious disease.

[15]  I. Morrissey,et al.  The bactericidal activity of levofloxacin compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae. , 1997, The Journal of antimicrobial chemotherapy.

[16]  D. Fish,et al.  The Clinical Pharmacokinetics of Levofloxacin , 1997, Clinical pharmacokinetics.

[17]  W. Yew,et al.  Short-course chemoprophylaxis evaluated in gold miners with chronic silicosis. , 1997 .

[18]  Nalin Rastogi,et al.  Spectrum of activity of levofloxacin against nontuberculous mycobacteria and its activity against the Mycobacterium avium complex in combination with ethambutol, rifampin, roxithromycin, amikacin, and clofazimine , 1996, Antimicrobial agents and chemotherapy.

[19]  D. Mortiboy,et al.  Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid , 1995, Antimicrobial agents and chemotherapy.

[20]  J. Froula,et al.  Quinolone antibiotics in therapy of experimental pneumococcal meningitis in rabbits , 1995, Antimicrobial agents and chemotherapy.

[21]  M. Hammerschlag.  Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae , 1994, Antimicrobial Agents and Chemotherapy.

[22]  M. Rogge,et al.  Activity of levofloxacin in a murine model of tuberculosis , 1994, Antimicrobial Agents and Chemotherapy.

[23]  M. Tanaka,et al.  Mechanistic study of inhibition of levofloxacin absorption by aluminum hydroxide , 1993, Antimicrobial Agents and Chemotherapy.

[24]  S. Takayama,et al.  Involvement of inhibitory and excitatory neurotransmitters in levofloxacin- and ciprofloxacin-induced convulsions in mice , 1993, Antimicrobial Agents and Chemotherapy.

[25]  J. Mcgregor,et al.  Comparative antibiotic susceptibilities of anaerobes associated with infections of the female reproductive tract. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  H. Hakusui,et al.  Effects of antacids, ferrous sulfate, and ranitidine on absorption of DR-3355 in humans , 1992, Antimicrobial Agents and Chemotherapy.

[27]  S. Takayama,et al.  Phototoxic potential of the new quinolone antibacterial agent levofloxacin in mice. , 1992, Arzneimittel-Forschung.

[28]  Wagai Nobuhiko,et al.  Quinolone antibacterial-agent-induced cutaneous phototoxicity: ear swelling reactions in Balb/c mice. , 1991 .

[29]  Wagai Nobuhiko,et al.  Phototoxic potential of quinolone antibacterial agents in Balb/c mice , 1990 .

[30]  M. Tanaka,et al.  Sub-inhibitory and post-antibiotic effects of an optically active isomer of ofloxacin. , 1989, Arzneimittel-Forschung.

[31]  T. Une,et al.  In vitro activity of DR-3355, an optically active ofloxacin , 1988, Antimicrobial Agents and Chemotherapy.

[32]  R. Jones,et al.  Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin. , 1994, Diagnostic microbiology and infectious disease.

[33]  B. Foleno,et al.  Induction of resistance of Streptococcus pneumoniae to quinolones in vitro. , 1993, Chemotherapy.